Knights of Columbus Asset Advisors LLC Has $31,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Knights of Columbus Asset Advisors LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 90.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 120 shares of the medical research company's stock after selling 1,182 shares during the quarter. Knights of Columbus Asset Advisors LLC's holdings in Amgen were worth $31,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of AMGN. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the 3rd quarter valued at about $29,000. Centricity Wealth Management LLC bought a new position in Amgen during the fourth quarter valued at approximately $25,000. Synergy Investment Management LLC purchased a new position in Amgen during the 4th quarter valued at approximately $34,000. Atala Financial Inc purchased a new position in shares of Amgen in the 4th quarter worth $34,000. Finally, Heck Capital Advisors LLC purchased a new stake in shares of Amgen during the 4th quarter valued at about $36,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN stock traded up $0.06 on Thursday, hitting $305.77. 1,736,805 shares of the company's stock traded hands, compared to its average volume of 2,542,168. The stock has a market cap of $164.26 billion, a price-to-earnings ratio of 40.50, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a fifty day moving average of $299.66 and a 200-day moving average of $298.46.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is currently 126.09%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Piper Sandler Companies restated an "overweight" rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Leerink Partners dropped their price objective on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Piper Sandler increased their target price on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Finally, UBS Group reissued a "hold" rating on shares of Amgen in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $314.04.

Insider Activity at Amgen

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 in the last ninety days. 0.69% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.